Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Sponsor: Boryung Pharmaceutical Co., Ltd
Summary
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
Official title: A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
276
Start Date
2024-05-21
Completion Date
2025-04
Last Updated
2024-05-22
Healthy Volunteers
No
Interventions
BR1019A
Subjects take the investigational products once a day for 12 weeks.
BR1019B
Subjects take the investigational products once a day for 12 weeks.
BR1019C
Subjects take the investigational products once a day for 12 weeks.
BR1019A-1
Subjects take the investigational products once a day for 12 weeks.
BR1019B-1
Subjects take the investigational products once a day for 12 weeks.
BR1019C-1
Subjects take the investigational products once a day for 12 weeks.
Locations (2)
Severance Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea